MGP.L Regulatory News (MGP)

11 May 2021

Medica Group Plc

Non-Executive Director Change

Medica Group Plc (LSE: MGP, "Medica" or the "Company"), the UK market leader in the provision of teleradiology services, announces that Steve Whittern has notified the Board of his intention to stand down as Senior Independent Non-Executive Director and Chairman of the Audit Committee ahead of the Company's Annual General Meeting (AGM) on 16 June 2021 and therefore will not be seeking re-election.

Steve joined the Medica Group Board on flotation in March 2017 and has supported the business as the Senior Independent Non-Executive Director, Chairman of the Audit Committee and member of the Remuneration and Nominations Committees. The Company has already made good progress in the search for a replacement and will update the market in due course.

Roy Davis, Chairman of Medica, commented:

"On behalf of myself, the Board and the Company, I would like to thank Steve for his valuable contribution to both the Audit Committee and broader business during his tenure. He has played an important role in establishing Medica as a strong public company since the IPO in 2017. It has been a pleasure to work with him and we wish him the very best for the future."

Steve Whittern, Senior Independent Non-Executive Director & Chair of the Audit Committee, added:

"I have enjoyed working with the Medica team since flotation and believe it is the right time for me to step down as a Non-Executive Director. Medica is a leader in teleradiology services and, as it continues to execute on its growth strategy, is well-placed to capitalise on the attractive, growing market opportunity. I wish the Company every success in what I expect to be a very exciting future."

For further information, please contact:  

About Medica Group PLC

Medica is the market leader in the UK and Ireland for the provision of teleradiology services, providing outsourced interpretation and reporting of MRI (magnetic resonance imaging), CT (computerised tomography), ultrasound and plain film (x-ray) images. Medica also offers diabetic retinopathy screening in Ireland.

Medica contracts with the largest pool of consultant radiologists in the UK and Ireland, performing remote access teleradiology across its customer base of more than 100 NHS Trusts in the UK, the Irish HSE, private hospital and insurance groups, as well as diagnostic imaging companies. This enables the Company to offer a fast, responsive service. In addition, Medica operates in Australia and New Zealand through MedX, a 50:50 Joint Venture with Integral Diagnostics Limited Pty.

The Company currently offers two primary services to hospital radiology departments:

· NightHawk - urgent reporting service

· Elective - includes routine cross-sectional reporting on MRI and CT scans, and routine plain film reporting on x-ray images.

These services are underpinned by Medica's bespoke, secure IT platform that provides market-leading linkage between a hospital's Radiology Information System (RIS) and consultant radiologists who contract with the Company. Direct RIS access ensures that where the wider patient medical history is available, it can be reviewed by the consultant as part of every report.

Through its subsidiary, RadMD, in the United States, Medica also provides pharmaceutical and biotech clients and contract research organisations (CROs) with high quality, complex imaging services for international clinical trials. RadMD has gained vast experience in the space, having contributed to over 500 international clinical trials, in all phases of clinical research from proof of concept to phase III and with expertise in oncology, as well as a wider range of therapeutic areas including medical devices, neurology and cardiovascular.

For more information please visit: www.medicagroupplc.com